Goldman Sachs Group Inc. Sells 190,795 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Goldman Sachs Group Inc. reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 11.0% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,541,610 shares of the biopharmaceutical company’s stock after selling 190,795 shares during the quarter. Goldman Sachs Group Inc. owned 1.22% of Halozyme Therapeutics worth $56,978,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. TD Asset Management Inc grew its holdings in shares of Halozyme Therapeutics by 517.0% during the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock worth $73,326,000 after purchasing an additional 1,662,390 shares in the last quarter. Norges Bank bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth $44,935,000. Epoch Investment Partners Inc. raised its position in shares of Halozyme Therapeutics by 250.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after buying an additional 831,199 shares in the last quarter. Boston Partners grew its position in Halozyme Therapeutics by 562.2% in the fourth quarter. Boston Partners now owns 552,392 shares of the biopharmaceutical company’s stock worth $20,218,000 after acquiring an additional 468,977 shares in the last quarter. Finally, LSV Asset Management purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at about $17,090,000. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $50.27 on Wednesday. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The company has a 50-day moving average price of $43.22 and a 200-day moving average price of $39.82. The company has a market cap of $6.40 billion, a price-to-earnings ratio of 20.77, a price-to-earnings-growth ratio of 0.50 and a beta of 1.28. Halozyme Therapeutics, Inc. has a 12 month low of $32.83 and a 12 month high of $53.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The company had revenue of $195.88 million for the quarter, compared to the consensus estimate of $201.72 million. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on HALO. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, June 4th. Piper Sandler cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $48.00 to $51.00 in a research note on Friday, June 7th. Benchmark reissued a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Finally, JMP Securities decreased their price objective on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $54.13.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total value of $384,900.00. Following the sale, the senior vice president now owns 168,176 shares in the company, valued at $6,473,094.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 30,000 shares of company stock worth $1,338,800 over the last quarter. 2.70% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.